Australian drug maker InterPharma will not appeal a ruling that dismissed its challenge to the validity of global pharmaceutical giant Pfizer’s patent for sedative drug Precedex.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A court has found Ariosa Diagnostics infringed a patent held by Sequenom for a noninvasive prenatal genetic test, and ruled one claim of the patent invalid for lack of fair basis.
Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan’s request for an order blocking Sun from launching its own generic version of the drug.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
GM Holden has lost most of its case for design infringement against a company that imported and distributed spare car parts used to “up-spec” lower range Holden models, in the court’s first test of the Designs Act’s repair defence.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Tech giant Apple can move forward with its plans to register the “HealthKit” trade mark for its popular health and fitness tracking app after resolving a dispute with an Australian startup over the mark.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.